Evidence map›Paper›PMID 39070150›Full record

ArticleFrontiers in oncology2024

Case report: Treatment response of NF-1-associated bladder ganglioneuroma to trametinib.

Marcus C Y Chan, Kevin K F Fung, Wai-Fu Ng, Ho-Ming Luk, Dennis T L Ku, Anthony P Y Liu

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Marcus C Y ChanDepartment of Paediatrics and Adolescent Medicine, Queen Mary Hospital, Hong Kong, Hong Kong SAR, China.
Kevin K F FungDepartment of Radiology, Hong Kong Children's Hospital, Hong Kong, Hong Kong SAR, China.
Wai-Fu NgDepartment of Pathology, Hong Kong Children's Hospital, Hong Kong, Hong Kong SAR, China.
Ho-Ming LukClinical Genetics Service Unit, Hong Kong Children's Hospital, Hong Kong, Hong Kong SAR, China.
Dennis T L KuDepartment of Paediatrics and Adolescent Medicine, Hong Kong Children's Hospital, Hong Kong, Hong Kong SAR, China.
Anthony P Y LiuDepartment of Paediatrics and Adolescent Medicine, Queen Mary Hospital, Hong Kong, Hong Kong SAR, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present the clinical course of a 4-year-old girl with neurofibromatosis type 1-associated, unresectable, symptomatic urinary bladder ganglioneuroma. She was initially trialed on sirolimus without response and subsequently responded to MEK inhibitor trametinib, with improvement clinically and radiographically over 10 months. This report broadens the repertoire of therapeutic strategies for MEK inhibition in diseases related to the MAPK pathway.

Indexed as

ganglioneuromaMAPK pathwayMEK inhibitorneurofibromatosis type 1 (NF-1)targeted therapy

Identifiers

PMID39070150
PMCPMC11272527

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.